Tat analog + AT1002 analog (AT-1002)
Sequence: GRKKRRQRRRCG | FCIGRLCG
| Experiment Id | EXP001847 |
|---|---|
| Paper | Development of an Efficient Transdermal Delivery System of Small Interfering RNA Using Functional Pe |
| Peptide | Tat analog + AT1002 analog (AT-1002) |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | Tat 32 µg + AT1002 400 µg per application |
| Rna Concentration | 5 µg fluorescent siRNA per application; 10 h |
| Mixing Ratio | Tat/siRNA N/P = 10 + AT1002 400 µg (TatAT1002 condition) |
| Formulation Format | Topical Tat/siRNA complex + AT1002 co-formulation for transdermal delivery |
| Formulation Components | Tat/siRNA complexes mixed with AT1002 and applied to tape-stripped mouse skin |
| Size Nm | 70.00 |
| Zeta Mv | 4.00 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | ICR mice (male, 6-week); back skin tape-stripped; topical 10 h |
| Administration Route | Topical application to tape-stripped dorsal skin (25 µL); confocal imaging |
| Output Type | In vivo uptake/distribution in skin (confocal microscopy) |
| Output Value | Strongest and widest siRNA localization (hair follicles + epidermal/dermal layers), higher brightness vs Tat or AT1002 alone |
| Output Units | |
| Output Notes | Combination improves both RNase stability and transdermal penetration depth/coverage. |
| Toxicity Notes | |
| Curation Notes |